key: cord-0965507-2si237ab
authors: Rana, E. A.; Dutta, P.; Islam, M. S.; Nizami, T. A.; Das, T.; Chowdhury, S.; Das, G. B.
title: Severity assessment of single dose Oxford-AstraZeneca vaccinated individuals infected with SARS CoV-2 in the Southeast Bangladesh
date: 2021-05-11
journal: nan
DOI: 10.1101/2021.05.10.21256529
sha: 9e023ba15d1266d2e70f1656aa303780ee18b40c
doc_id: 965507
cord_uid: 2si237ab

The present global endeavor to uncover the most effective vaccines against severe acute respiratory syndrome coronavirus (SARS-CoV-2) that can tremendously prevent transmission, infection and significantly reduce public health risk. COVID-19 vaccination program is underway in different parts of the world including Bangladesh but till to date there is no available health data revealed among the vaccinated peoples. We conducted a cross-sectional study from February 15 to April 15, 2021 to assess the health status of 1st dose Oxford-AstraZeneca vaccinated individuals infected with SARS CoV-2. Standard virological method, real-time reverse transcriptase-polymerase chain reaction (RT-qPCR) was performed to detect SARS-CoV-2 and the different health parameters from vaccinated individuals were collected through direct mobile phone contact using pre-structured questionnaires. A total of 6146 suspected samples were tested and 1752 were found positive for SARS-CoV-2, of them 200 individuals were identified who received 1st dose of COVID-19 vaccine. Within the test period, majority of male (65.6%) and female (34.4%) carried moderate numbers of viruses which comprise between 30.01-35 cyclic threshold (ct) values. Among the vaccinated individuals, 165 (82.5%; 95% CI: 76.51 - 87.5) persons were not hospitalized and 177 (88.5%; 95% CI: 83.24 - 92.57) did not show any respiratory difficulties. Only a few (16) (8%; 95% CI: 4.64 - 12.67) of COVID-19 positive patients needed extra oxygen support and 199 (99.5%; 95% CI: 97.25 - 99.99) individuals did not require any intensive care unit (ICU) interference. Overall, oxygen saturation was recorded around 96.8% and respiratory difficulties did not extend more than 5 days, irrespective of age and sex during the infection period. Within the vaccinated COVID-19 positive individuals 113 (56.5%; 95% CI: 49.33 - 63.48) and 111(55.5%; 95% CI: 48.32 - 62.51) persons have normal physiological taste and smell. However, we have found a larger proportion of vaccinated persons (129) (64.5%; 95% CI: 57.44 - 71.12) carrying different comorbidity, among them high blood pressure 36 (27.9%; 95% CI, 20.37 - 36.48) and diabetes 32 (24.8%; 95% CI: 17.63 - 33.18) were found more prevalent. Moreover, the significant finding of the present study was 199 (99.5%; 95% CI: 97.25 - 99.99) vaccinated individuals survived with good health conditions and became negative in RT-qPCR. The authors suggest that health risk assessment among the COVID-19 vaccinated persons when infected with SARS-CoV-2 is crucial and time demanding task for the whole world. However, the present study illustrates that the administration of the 1st dose Oxford-AstraZeneca vaccine significantly reduces health risk during the COVID-19 infection period.

Severe acute respiratory syndrome coronavirus (SARS-CoV-2) pandemic is envisaged as number one global public health crisis due to its high morbidity and drastic fatality rate. Since the reporting of the outbreak, it has infected over 153 million of which over 3.2 million people died (Worldometer 2021). Longer survival rate of virus in different environmental conditions and unprecedented speed of transmission from human-to-human can aggravate the present ongoing outbreak situations (Negahdaripour, 2020) . Additionally, the virus causes severe flu-like symptoms with greater respiratory difficulties and reports that one infected or carrier individual can easily infect others (J. Xu et al., 2020) . However, the estimated reproductive number (R 0 ) of SARS-CoV-2 is 2.2, i.e., one COVID-19 individual is able to transmit the virus to 2.2 other healthy individuals (Li Q et al., 2020) . To overcome the devastating effects of the virus on human health, a highly effective vaccine is a crying need. For COVID- 19 Standard 2021). However, the magnitude of vaccine response to the virus particle is widely varied. The significant consideration is the re-infection of previously infected or vaccinated individuals with the same virus is possible due to its high and rapid mutation rate as well as the nature of viruses (Hansen et al., 2021). However, human coronavirus does not induce lifelong immunity and antibody response due to rapid fall of humoral immunity (Amanat and Florian Krammer,2020) . Moreover, the measurement of protective antibody titer against SARS-CoV-2 after vaccination is still underdeveloped. Unfortunately, after receiving the first dose (approximately 5 × 10¹ viral particles) of the Oxford-AstraZeneca vaccine, a number of ⁰ 

After sorting, all the data were inserted in STATA-IC 13® software to perform statistical analysis. Descriptive analysis was performed to calculate the prevalence of target outcome. The prevalence of SARS-CoV-2 was calculated considering the number of COVID-19 positive cases as the numerator divided by the total number samples as the denominator. The 95% confidence interval of the prevalence values was calculated by the modified Wald method using the Graph Pad Quickcalcs Online tool (www.graphpad.com/quickcalcs/). 

The primary and well defined symptoms of the coronavirus are likely fever, coughing and sneezing. In our findings, we noticed 144 (72%; 95% CI: 65.23 -78.1) individuals appear fever with variable ranges while 182 (91%; 95% CI: 86.15-94.58) and 89 (44.5%; 95% CI: 37.49-51.68) COVID 19 patients didn't have any sneezing and coughing during the infection period ( Table 1) . Irrespective of ages and sex, it was observed that within the vaccinated individulas the common symptoms of sneezing and coughing were not extended more than 3 days and 7 days, respectively. However, 113 (56.5%; 95% CI: 49.33 -63.48) and 111 (55.5%; 95% CI: 48.32 -62.51) vaccinated individuals had their normal physiological taste and smell function during the infection period.

Shortness of breathing is one of the most significant symptoms of the COVID-19 patients. We 

The authors have no conflict of interest to declare.

EAR planned, designed the study and prepared the initial draft of the manuscript. EAR, PD, MSI, TAN, and TD executed laboratory tasks, data entry and manuscript preparation. PD and TD analysed and summarised the data. SC and GBD supervised the study and revised the final manuscript. All authors read and approved the final manuscript. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted May 11, 2021. ; https://doi.org/10.1101/2021.05.10.21256529 doi: medRxiv preprint

SARS-CoV-2 vaccines in development

The battle against COVID-19: Where do we stand now?

Systematic comparison of two animal to human transmitted human 4. coronaviruses: SARS-CoV-2 and SARS-CoV

Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia

Oxford-AstraZeneca COVID-19 vaccine efficacy

The SARS-CoV-2 vaccine pipeline: an overview. Current tropical medicine reports

SARS-CoV-2 vaccines: status report

Molecular detection and prevalence of SARS-CoV-2 during the early outbreak in southern Bangladesh

Laboratory Testing for Coronavirus Disease 2019 (COVID-19) in Suspected Human Cases. World Health Organization

Worldometer

List of Districts-Chattogram Division

The Business Standard

mRNA vaccine and ChAdOx1 adenovirus vector vaccine on symptomatic disease, hospitalisations and mortality in older adults in

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised

Medicines and Healthcare products Regulatory Agency. Regulatory approval of COVID-19 vaccine AstraZeneca

Single-dose Oxford-AstraZeneca COVID-19 vaccine followed by a 12-week booster

Coronavirus vaccine tracker

Oxford-AstraZeneca COVID-19 vaccine efficacy

The authors acknowledge CMC and BITID for providing samples from different regions of the